Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study

Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS n...

Descripción completa

Detalles Bibliográficos
Autores principales: Maugeais, Madeleine, Péron, Julien, Dalle, Stéphane, Boespflug, Amélie, Duruissaux, Michaël, Corbaux, Pauline, Reverdy, Thibault, Sahin, Gulsum, Rabier, Aurélie, Lopez, Jonathan, Freymond, Nathalie, Maillet, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855949/
https://www.ncbi.nlm.nih.gov/pubmed/36672591
http://dx.doi.org/10.3390/biomedicines11010083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855949/
https://www.ncbi.nlm.nih.gov/pubmed/36672591
http://dx.doi.org/10.3390/biomedicines11010083

Ejemplares similares